Clinical trials are essential to understanding the efficacyof medical interventions. The ethical underpinnings of thistype of research involving human subjects, codified in the BelmontReport1 and the Declaration of Helsinki,2 require that the resultsbe publicly available to inform medical practice as well asfuture research. In addition, basic principles of evidence-basedpractice require the analysis of all data on a given topic;the practice of publishing only some results, but not others,3,4undermines our collective ability to make rational decisionsabout medical care.
In Section 801 of the Food and Drug Administration (FDA) AmendmentsAct,5 enacted in . . . [Full Text of this Article]
Registration Requirements
Results-Reporting Requirements
Clinical Trials Results Databases
The Need for Additional Legislation
Conclusions
Source Information
Dr. Wood is managing director of Symphony Capital and a Professor of Medicine and Pharmacology at Weill Medical College of Cornell University — both in New York.
This article has been cited by other articles:
Endre, Z. H., Pickering, J. W.
(2009). Outcome definitions in non-dialysis intervention and prevention trials in acute kidney injury (AKI). Nephrol Dial Transplant
0: gfp501v1-gfp501
[Abstract][Full Text]
Califf, R. M., Harrington, R. A., Blazing, M. A.
(2009). Premature Release of Data from Clinical Trials of Ezetimibe. NEJM
361: 712-717
[Full Text]
O'Connor, A. B.
(2009). The Need for Improved Access to FDA Reviews. JAMA
302: 191-193
[Full Text]
Tse, T., Williams, R. J., Zarin, D. A.
(2009). Reporting "Basic Results" in ClinicalTrials.gov. Chest
136: 295-303
[Full Text]